NasdaqGM:AXSMPharmaceuticals
Mental Health Stocks Gaining Fresh Attention After Eli Lilly’s Psychedelic Deal
The Eli Lilly move on AtaiBeckley has pushed psychedelics and mental health treatments back into the spotlight, and it is giving investors fresh reasons to reassess which stocks are most exposed to this news. With a multi billion dollar cash deal, a premium offer, and a late stage DMT program now under a big pharma umbrella, attention is turning to other companies tied to similar themes. This article breaks down three stocks from our mental health and psychedelic treatments screener that...